SARS-CoV-2 Vaccine Strain Selection: Guidance From Influenza.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 36424890.
- Also identified by DOI 10.1093/infdis/jiac454 and PMC identifier 10205617.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When first approved, many hoped that the SARS-CoV-2 vaccine would provide long-term protection after a primary series. Waning of immunity and continued appearance of new variants has made booster inoculations necessary. The process is becoming increasingly similar to that used for annual updating of the influenza vaccine. The similarity has become even more apparent with selection of BA.4/BA.5 as the Omicron strain of the updated bivalent (Original + Omicron) COVID-19 vaccines. It is hoped that, if COVID-19 develops winter seasonality, SARS-CoV-2 vaccines will require only annual review to determine if updates are necessary. Recommendations on whom should receive the booster would be based on conditions at that time.
Medical subject headings
- Influenza Vaccines
- Influenza, Human
- COVID-19